Fresenius Medical Care, a leading global provider of products and services for individuals with renal diseases, is headquartered in the United States. Founded in 1996, the company has established a strong presence in North America, Europe, and Asia, focusing on dialysis services and the manufacture of dialysis equipment. With a commitment to innovation, Fresenius Medical Care offers a comprehensive range of products, including dialysis machines and consumables, which are distinguished by their advanced technology and patient-centric design. The company is recognised for its significant market position, serving millions of patients worldwide and achieving notable milestones in improving patient outcomes. As a key player in the healthcare industry, Fresenius Medical Care continues to lead in the development of integrated care solutions, enhancing the quality of life for those affected by chronic kidney disease.
How does Fresenius Medical Care's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius Medical Care's score of 85 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Fresenius Medical Care reported total carbon emissions of approximately 3,680.8 tonnes CO2e, with Scope 1 emissions at about 360.8 tonnes CO2e and Scope 2 emissions at approximately 450.6 tonnes CO2e. The company also disclosed significant Scope 3 emissions, totalling about 7,856.5 tonnes CO2e, which includes categories such as purchased goods and services (approximately 1,385,959 tonnes CO2e) and employee commute (about 192,383 tonnes CO2e). Fresenius Medical Care has set ambitious climate commitments, aiming to reduce its combined direct (Scope 1) and indirect (Scope 2) greenhouse gas emissions by 50% by 2030, using 2020 as the baseline year. This target is part of their broader sustainability strategy and reflects their commitment to addressing climate change. The company is also committed to achieving net-zero emissions across all scopes by 2050, as indicated by their Science Based Targets initiative (SBTi) commitment. The emissions data and reduction targets are sourced from Fresenius Medical Care AG, the parent company, and reflect their ongoing efforts to enhance sustainability within the healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000.0 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000.0 |
Fresenius Medical Care's Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 17640922% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fresenius Medical Care has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Fresenius Medical Care's sustainability data and climate commitments